American HealthCare Capital is pleased to present a 340b pharmacy providing Specialty, Retail, and Compounding medications to patients throughout the state of Florida. The pharmacy has been in business since 2013 and has been growing steadily over the past four years. Their medication therapies have been focused on Dermatology, Crohn’s/GI, Hepatitis, HIV/Aids, Multiple Sclerosis, Oncology, Rheumatology, Ophthalmology, and Transplant. In recent months there has been tremendous growth into other therapies, such as autoimmune. The specialty pharmacy revenue and patient growth is bolstered by the implementation of proprietary software built on the platform of PioneerRX. Their software allows them to track the entire patient continuum and ensure therapeutic compliance with detailed documentation. The data they generate is proprietary, some of which they sell back to drug manufacturers. The company’s payer mix is 97% Medicare and Medicaid and 3% Cash. Gross revenues have shown consistent growth over the years. In 2017, gross revenues exceeded their projections for the year at $52,800,000, with an adjusted EBITDA of $1,914,000. They are expecting gross revenues to grow 20% in 2018. The current owners have decided to step away from the business to address personal issues, but are willing to stay involved to ensure a smooth transition and future growth of the company. The entire staff, including an experienced Pharmacist-in-Charge are expected to stay on with the new ownership. The asking price for this opportunity is $9.75 Million plus inventory.